New approaches for patients with advanced radioiodine-refractory thyroid cancer
作者机构：Division of EndocrinologyHospital de Clinicas Jose de San MartinUniversity of Buenos AiresBuenos Aires 1120Argentina Clinic for Endocrinology and DiabetologyLugano Regional HospitalEnte Ospedaliero CantonaleLugano 1111Switzerland Faculty of Biomedical SciencesUniversitàdella Svizzera ItalianaLugano 1111Switzerland
出 版 物：《World Journal of Clinical Oncology》 (世界临床肿瘤学杂志（英文版）)
年 卷 期：2022年第13卷第1期
页 面：9-27页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：Advanced differentiated thyroid cancer Radioactive iodine refractory thyroid cancer Multikinase inhibitors Systemic therapy Target therapy
摘 要：The cumulative evidence over the past decades has shown that the incidence of differentiated thyroid carcinoma(DTC)has exponentially *** 10%of patients with DTC exhibit recurrent or metastatic disease,and about two-thirds of the latter will be defined as refractory to radioactive iodine(RAIR)*** this condition implies 10-year survival rates less than 10% after detection,using available treatments,such as systemic and targeted therapies,have become increasingly *** initiation of these treatments aims to reach stabilization,tumor volume reduction,and/or symptom improvement and it should be decided by highly specialized endocrinologists/oncologists on the basis of patient’s *** that despite enlarged progression-free survival was proven,multikinase inhibitors remain non-curative,their benefits last for a limited time and the side effects potentially cause harm and quality of life *** this context,molecular testing of cancer cells provides a promising spectrum of targeted therapies that offer increased compatibility with individual patient needs by improving efficacy,progression free survival,overall survival and adverse events *** review article aims to provide a summary of the current therapeutic strategies in advanced RAIR-DTC,including approved target therapies as well as those for off-label use,RAI resensitization agents,and immunotherapy.
维普期刊数据库